Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cytodiagnosis | 15 | 2024 | 447 | 4.410 |
Why?
|
Lung Neoplasms | 61 | 2024 | 13381 | 3.540 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 27 | 2023 | 5314 | 2.400 |
Why?
|
Biopsy, Fine-Needle | 19 | 2024 | 1118 | 2.010 |
Why?
|
Thyroid Nodule | 7 | 2023 | 764 | 1.730 |
Why?
|
Specimen Handling | 5 | 2020 | 702 | 1.720 |
Why?
|
Adenocarcinoma | 20 | 2024 | 6345 | 1.640 |
Why?
|
Thyroid Neoplasms | 11 | 2023 | 2332 | 1.620 |
Why?
|
Adenocarcinoma, Follicular | 5 | 2023 | 323 | 1.360 |
Why?
|
Laboratories | 3 | 2022 | 458 | 1.260 |
Why?
|
Molecular Diagnostic Techniques | 5 | 2023 | 610 | 1.250 |
Why?
|
Thyroid Gland | 6 | 2022 | 1170 | 1.170 |
Why?
|
Bronchoscopy | 10 | 2022 | 909 | 0.880 |
Why?
|
Pleural Effusion, Malignant | 1 | 2024 | 106 | 0.870 |
Why?
|
Lung | 17 | 2024 | 10002 | 0.820 |
Why?
|
Bronchi | 4 | 2021 | 845 | 0.770 |
Why?
|
Salivary Glands | 1 | 2022 | 229 | 0.730 |
Why?
|
Granuloma | 2 | 2020 | 328 | 0.670 |
Why?
|
Neoplasm Staging | 14 | 2024 | 11120 | 0.670 |
Why?
|
Receptor Protein-Tyrosine Kinases | 11 | 2022 | 1626 | 0.660 |
Why?
|
Antigens, CD1d | 2 | 2019 | 228 | 0.650 |
Why?
|
Mutation | 19 | 2024 | 30053 | 0.610 |
Why?
|
Societies, Scientific | 1 | 2019 | 222 | 0.610 |
Why?
|
Natural Killer T-Cells | 2 | 2019 | 322 | 0.600 |
Why?
|
Mediastinal Diseases | 1 | 2018 | 91 | 0.590 |
Why?
|
Quality Assurance, Health Care | 2 | 2018 | 2169 | 0.580 |
Why?
|
Quality Improvement | 4 | 2021 | 3802 | 0.550 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2016 | 56 | 0.540 |
Why?
|
Societies, Medical | 4 | 2023 | 3905 | 0.530 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2018 | 201 | 0.530 |
Why?
|
Tomography, X-Ray Computed | 20 | 2024 | 20568 | 0.480 |
Why?
|
Humans | 122 | 2024 | 761596 | 0.440 |
Why?
|
Diagnostic Errors | 3 | 2022 | 1265 | 0.420 |
Why?
|
Protein Kinase Inhibitors | 14 | 2023 | 5672 | 0.420 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 787 | 0.410 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 899 | 0.410 |
Why?
|
Pathology, Surgical | 2 | 2021 | 151 | 0.400 |
Why?
|
Carcinoma, Papillary | 2 | 2021 | 785 | 0.400 |
Why?
|
Heart Valve Diseases | 2 | 2021 | 1027 | 0.400 |
Why?
|
Multiple Pulmonary Nodules | 3 | 2020 | 173 | 0.400 |
Why?
|
Pathology, Clinical | 3 | 2022 | 376 | 0.400 |
Why?
|
Receptors, LDL | 2 | 2019 | 488 | 0.400 |
Why?
|
Small Cell Lung Carcinoma | 4 | 2020 | 423 | 0.390 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1745 | 0.380 |
Why?
|
Lymph Nodes | 3 | 2018 | 3465 | 0.380 |
Why?
|
Atherosclerosis | 4 | 2019 | 3407 | 0.380 |
Why?
|
Laboratories, Hospital | 3 | 2021 | 192 | 0.370 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1115 | 0.370 |
Why?
|
Lipid Metabolism | 1 | 2019 | 1902 | 0.370 |
Why?
|
Molecular Targeted Therapy | 4 | 2018 | 2811 | 0.360 |
Why?
|
Solitary Pulmonary Nodule | 3 | 2019 | 278 | 0.360 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3639 | 0.350 |
Why?
|
Internet | 1 | 2022 | 3093 | 0.350 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2022 | 2510 | 0.340 |
Why?
|
Arteriosclerosis | 2 | 2005 | 1055 | 0.340 |
Why?
|
Retrospective Studies | 32 | 2024 | 80647 | 0.340 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2020 | 2827 | 0.330 |
Why?
|
Endosonography | 3 | 2020 | 609 | 0.330 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2018 | 571 | 0.320 |
Why?
|
Cholesterol, VLDL | 1 | 2008 | 70 | 0.310 |
Why?
|
Patient Care | 3 | 2023 | 622 | 0.290 |
Why?
|
Practice Guidelines as Topic | 6 | 2017 | 7391 | 0.290 |
Why?
|
Carcinoma | 2 | 2016 | 2330 | 0.290 |
Why?
|
Risk | 5 | 2023 | 9610 | 0.280 |
Why?
|
Immunohistochemistry | 8 | 2019 | 11076 | 0.270 |
Why?
|
Calcinosis | 1 | 2015 | 1469 | 0.270 |
Why?
|
Prognosis | 12 | 2024 | 29629 | 0.270 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2917 | 0.270 |
Why?
|
Pneumonia | 1 | 2018 | 2143 | 0.260 |
Why?
|
Aged, 80 and over | 18 | 2024 | 58984 | 0.260 |
Why?
|
DNA Mutational Analysis | 4 | 2018 | 4111 | 0.260 |
Why?
|
Idiopathic Pulmonary Fibrosis | 2 | 2022 | 515 | 0.260 |
Why?
|
Aged | 34 | 2024 | 169310 | 0.250 |
Why?
|
Aortic Valve | 1 | 2015 | 1955 | 0.250 |
Why?
|
Female | 54 | 2024 | 392705 | 0.250 |
Why?
|
Mediastinum | 2 | 2018 | 266 | 0.250 |
Why?
|
Lipoproteins | 3 | 2019 | 881 | 0.240 |
Why?
|
Precancerous Conditions | 1 | 2011 | 980 | 0.240 |
Why?
|
Argon Plasma Coagulation | 2 | 2021 | 25 | 0.240 |
Why?
|
Adoptive Transfer | 1 | 2007 | 819 | 0.230 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 5305 | 0.230 |
Why?
|
Male | 45 | 2024 | 360846 | 0.230 |
Why?
|
Gene Amplification | 3 | 2018 | 1089 | 0.230 |
Why?
|
Bronchial Neoplasms | 2 | 2014 | 110 | 0.220 |
Why?
|
Genetic Testing | 1 | 2017 | 3537 | 0.220 |
Why?
|
Biopsy, Needle | 5 | 2018 | 1626 | 0.220 |
Why?
|
Hemorheology | 1 | 2003 | 144 | 0.220 |
Why?
|
Amoeba | 1 | 2023 | 20 | 0.210 |
Why?
|
Aortic Valve Stenosis | 1 | 2015 | 2001 | 0.210 |
Why?
|
Aortic Diseases | 1 | 2008 | 735 | 0.210 |
Why?
|
Tracheobronchomalacia | 2 | 2021 | 131 | 0.200 |
Why?
|
Proto-Oncogene Proteins | 6 | 2017 | 4514 | 0.200 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2018 | 1745 | 0.200 |
Why?
|
Pyrazoles | 4 | 2017 | 2009 | 0.190 |
Why?
|
Middle Aged | 32 | 2024 | 220921 | 0.190 |
Why?
|
Hand Deformities, Congenital | 1 | 2022 | 174 | 0.190 |
Why?
|
Curettage | 1 | 2021 | 74 | 0.180 |
Why?
|
Carbazoles | 2 | 2022 | 220 | 0.180 |
Why?
|
Amino Acyl-tRNA Synthetases | 1 | 2021 | 88 | 0.180 |
Why?
|
Cell Biology | 1 | 2021 | 90 | 0.180 |
Why?
|
Fatal Outcome | 4 | 2020 | 1835 | 0.180 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2017 | 2425 | 0.180 |
Why?
|
Pyridines | 4 | 2017 | 2875 | 0.180 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2007 | 1784 | 0.170 |
Why?
|
Superior Vena Cava Syndrome | 1 | 2020 | 56 | 0.170 |
Why?
|
Tracheal Stenosis | 1 | 2021 | 228 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9280 | 0.160 |
Why?
|
Pulmonary Sclerosing Hemangioma | 1 | 2018 | 2 | 0.160 |
Why?
|
Neoplasms | 3 | 2022 | 22173 | 0.160 |
Why?
|
Total Quality Management | 1 | 2020 | 265 | 0.160 |
Why?
|
Killer Cells, Natural | 2 | 2007 | 2201 | 0.160 |
Why?
|
Tomography, Optical Coherence | 2 | 2022 | 2917 | 0.160 |
Why?
|
Myositis | 1 | 2021 | 271 | 0.160 |
Why?
|
Tumor Burden | 3 | 2020 | 1892 | 0.150 |
Why?
|
Truth Disclosure | 1 | 2022 | 434 | 0.150 |
Why?
|
Pleurodesis | 1 | 2018 | 46 | 0.150 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2024 | 617 | 0.150 |
Why?
|
Prosthesis-Related Infections | 1 | 2023 | 487 | 0.150 |
Why?
|
Lymphatic Metastasis | 2 | 2018 | 2915 | 0.150 |
Why?
|
Genomics | 4 | 2024 | 5821 | 0.150 |
Why?
|
Bronchiolitis | 1 | 2024 | 485 | 0.150 |
Why?
|
Trachea | 2 | 2021 | 1089 | 0.150 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2020 | 755 | 0.150 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 15266 | 0.140 |
Why?
|
Communicable Disease Control | 2 | 2022 | 846 | 0.140 |
Why?
|
Pacemaker, Artificial | 1 | 2023 | 807 | 0.140 |
Why?
|
Biopsy | 3 | 2022 | 6766 | 0.140 |
Why?
|
Microscopy, Fluorescence | 1 | 2024 | 2645 | 0.140 |
Why?
|
Organophosphorus Compounds | 1 | 2018 | 206 | 0.140 |
Why?
|
Radiography, Interventional | 1 | 2024 | 1121 | 0.140 |
Why?
|
Adult | 22 | 2024 | 221210 | 0.140 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2021 | 384 | 0.140 |
Why?
|
Thorax | 1 | 2020 | 555 | 0.140 |
Why?
|
Needles | 1 | 2020 | 451 | 0.140 |
Why?
|
Cervix Uteri | 1 | 2021 | 570 | 0.140 |
Why?
|
Antineoplastic Agents | 9 | 2018 | 13642 | 0.140 |
Why?
|
Leukocytes | 1 | 2005 | 2026 | 0.140 |
Why?
|
Mediastinal Neoplasms | 1 | 2020 | 401 | 0.140 |
Why?
|
Exons | 2 | 2023 | 2391 | 0.140 |
Why?
|
Adaptive Immunity | 2 | 2019 | 726 | 0.130 |
Why?
|
Organ Specificity | 2 | 2016 | 1968 | 0.130 |
Why?
|
Sensitivity and Specificity | 4 | 2017 | 14665 | 0.130 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 162 | 0.130 |
Why?
|
False Positive Reactions | 1 | 2018 | 957 | 0.130 |
Why?
|
Chondrosarcoma | 1 | 2018 | 296 | 0.130 |
Why?
|
Benchmarking | 1 | 2022 | 1045 | 0.130 |
Why?
|
Carotid Artery, Internal | 1 | 2018 | 445 | 0.130 |
Why?
|
CCAAT-Binding Factor | 1 | 2015 | 21 | 0.120 |
Why?
|
Airway Obstruction | 1 | 2020 | 661 | 0.120 |
Why?
|
HIV | 2 | 2023 | 1582 | 0.120 |
Why?
|
Neoplasm Invasiveness | 2 | 2020 | 3597 | 0.120 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2014 | 76 | 0.120 |
Why?
|
Baths | 1 | 2014 | 53 | 0.120 |
Why?
|
Tissue Preservation | 1 | 2015 | 174 | 0.120 |
Why?
|
Workload | 1 | 2020 | 844 | 0.120 |
Why?
|
Metaplasia | 1 | 2015 | 322 | 0.120 |
Why?
|
Gene Rearrangement | 2 | 2017 | 1125 | 0.120 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 678 | 0.120 |
Why?
|
Alveolitis, Extrinsic Allergic | 1 | 2014 | 63 | 0.120 |
Why?
|
Autopsy | 1 | 2018 | 1009 | 0.110 |
Why?
|
Amyloidosis | 1 | 2021 | 817 | 0.110 |
Why?
|
Water Microbiology | 1 | 2014 | 113 | 0.110 |
Why?
|
Phosphogluconate Dehydrogenase | 1 | 2013 | 22 | 0.110 |
Why?
|
Sputum | 1 | 2016 | 506 | 0.110 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 452 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2018 | 491 | 0.110 |
Why?
|
Piperidines | 2 | 2022 | 1656 | 0.110 |
Why?
|
United States | 6 | 2023 | 72340 | 0.110 |
Why?
|
Tablets | 1 | 2014 | 148 | 0.110 |
Why?
|
Disease Models, Animal | 4 | 2018 | 18255 | 0.110 |
Why?
|
Pulmonary Atelectasis | 1 | 2014 | 143 | 0.110 |
Why?
|
Mesothelioma | 1 | 2019 | 807 | 0.110 |
Why?
|
Forced Expiratory Volume | 1 | 2018 | 1814 | 0.110 |
Why?
|
Respiratory Aspiration | 1 | 2014 | 89 | 0.110 |
Why?
|
Lung Diseases, Interstitial | 1 | 2021 | 918 | 0.100 |
Why?
|
Dyspnea | 2 | 2018 | 1347 | 0.100 |
Why?
|
Periodicals as Topic | 1 | 2023 | 1463 | 0.100 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2017 | 710 | 0.100 |
Why?
|
Workflow | 1 | 2017 | 851 | 0.100 |
Why?
|
SEER Program | 1 | 2017 | 1450 | 0.100 |
Why?
|
Hypercalcemia | 1 | 2014 | 423 | 0.100 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2020 | 4024 | 0.100 |
Why?
|
Esophagitis | 1 | 2013 | 164 | 0.100 |
Why?
|
Aorta | 1 | 2019 | 2041 | 0.100 |
Why?
|
Thymoma | 1 | 2013 | 188 | 0.100 |
Why?
|
ras Proteins | 2 | 2013 | 1054 | 0.090 |
Why?
|
Retinoblastoma Protein | 1 | 2015 | 672 | 0.090 |
Why?
|
Mice, Knockout | 3 | 2019 | 14417 | 0.090 |
Why?
|
Mitral Valve Insufficiency | 1 | 2021 | 1400 | 0.090 |
Why?
|
Chest Pain | 1 | 2018 | 1091 | 0.090 |
Why?
|
Sirolimus | 1 | 2018 | 1533 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2015 | 592 | 0.090 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2015 | 339 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2018 | 2865 | 0.090 |
Why?
|
False Negative Reactions | 1 | 2011 | 573 | 0.090 |
Why?
|
Radiography, Thoracic | 4 | 2020 | 1302 | 0.090 |
Why?
|
Alternative Splicing | 1 | 2015 | 1093 | 0.090 |
Why?
|
Adenoma, Oxyphilic | 1 | 2012 | 148 | 0.090 |
Why?
|
Cholesterol | 1 | 2019 | 2905 | 0.090 |
Why?
|
Myasthenia Gravis | 1 | 2013 | 214 | 0.090 |
Why?
|
Strongyloidiasis | 1 | 2010 | 27 | 0.090 |
Why?
|
Mice, Inbred C57BL | 3 | 2019 | 22174 | 0.090 |
Why?
|
Child | 4 | 2023 | 80158 | 0.090 |
Why?
|
Jejunal Diseases | 1 | 2010 | 46 | 0.090 |
Why?
|
Terminology as Topic | 2 | 2021 | 1530 | 0.090 |
Why?
|
Foreign Bodies | 1 | 2014 | 402 | 0.080 |
Why?
|
Duodenal Diseases | 1 | 2010 | 100 | 0.080 |
Why?
|
Disease-Free Survival | 2 | 2017 | 6815 | 0.080 |
Why?
|
Schistosomiasis mansoni | 1 | 2010 | 93 | 0.080 |
Why?
|
Salivary Gland Neoplasms | 1 | 2013 | 304 | 0.080 |
Why?
|
Diverticulum | 1 | 2010 | 137 | 0.080 |
Why?
|
Mice | 9 | 2019 | 81539 | 0.080 |
Why?
|
Diet, Atherogenic | 1 | 2008 | 92 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2021 | 2020 | 0.080 |
Why?
|
Embolization, Therapeutic | 1 | 2018 | 1418 | 0.080 |
Why?
|
Intracranial Aneurysm | 1 | 2018 | 1285 | 0.080 |
Why?
|
Immunocompetence | 1 | 2008 | 138 | 0.080 |
Why?
|
Models, Theoretical | 1 | 2020 | 3575 | 0.080 |
Why?
|
Sheep | 2 | 2021 | 1440 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1052 | 0.080 |
Why?
|
Communication | 1 | 2022 | 3875 | 0.070 |
Why?
|
Treatment Outcome | 9 | 2020 | 64685 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 11742 | 0.070 |
Why?
|
Risk Factors | 5 | 2015 | 74213 | 0.070 |
Why?
|
Disease Progression | 5 | 2020 | 13510 | 0.070 |
Why?
|
Animals | 13 | 2021 | 168475 | 0.070 |
Why?
|
Coronary Artery Disease | 1 | 2007 | 6403 | 0.070 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9542 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2017 | 2557 | 0.070 |
Why?
|
Heart Valve Prosthesis | 1 | 2015 | 1462 | 0.070 |
Why?
|
Arteries | 1 | 2011 | 1123 | 0.070 |
Why?
|
Myocarditis | 1 | 2014 | 788 | 0.070 |
Why?
|
Thyroidectomy | 1 | 2012 | 908 | 0.070 |
Why?
|
Diagnosis, Differential | 5 | 2024 | 12973 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2017 | 5247 | 0.070 |
Why?
|
Pyrimidines | 1 | 2018 | 3028 | 0.070 |
Why?
|
Pulmonary Artery | 1 | 2014 | 1927 | 0.060 |
Why?
|
Models, Animal | 2 | 2020 | 2112 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4016 | 0.060 |
Why?
|
Genotype | 3 | 2015 | 12990 | 0.060 |
Why?
|
Neoplasm Metastasis | 2 | 2015 | 4915 | 0.060 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2015 | 1553 | 0.060 |
Why?
|
Young Adult | 4 | 2019 | 59260 | 0.060 |
Why?
|
HIV Infections | 2 | 2023 | 17354 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1935 | 0.060 |
Why?
|
Lymphocyte Subsets | 1 | 2005 | 309 | 0.060 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1116 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4652 | 0.050 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2014 | 1462 | 0.050 |
Why?
|
Boston | 1 | 2015 | 9327 | 0.050 |
Why?
|
Cell Line, Tumor | 5 | 2018 | 16990 | 0.050 |
Why?
|
Immune System | 1 | 2007 | 796 | 0.050 |
Why?
|
Suction | 1 | 2023 | 266 | 0.050 |
Why?
|
Cholesterol, HDL | 1 | 2008 | 1814 | 0.050 |
Why?
|
Hyperlipidemias | 1 | 2007 | 771 | 0.050 |
Why?
|
Aniline Compounds | 2 | 2019 | 1069 | 0.050 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 2297 | 0.050 |
Why?
|
Facies | 1 | 2022 | 222 | 0.050 |
Why?
|
Argon | 1 | 2021 | 36 | 0.050 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 97 | 0.050 |
Why?
|
Tumor Necrosis Factors | 1 | 2021 | 107 | 0.050 |
Why?
|
Smad4 Protein | 1 | 2022 | 191 | 0.050 |
Why?
|
Pneumothorax | 1 | 2024 | 386 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5493 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4176 | 0.050 |
Why?
|
Pulmonary Embolism | 1 | 2014 | 2567 | 0.050 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2021 | 191 | 0.050 |
Why?
|
Triglycerides | 1 | 2008 | 2461 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2894 | 0.050 |
Why?
|
Planning Techniques | 1 | 2020 | 82 | 0.040 |
Why?
|
Smoking | 2 | 2017 | 9053 | 0.040 |
Why?
|
Papillary Muscles | 1 | 2021 | 192 | 0.040 |
Why?
|
Survival Rate | 3 | 2020 | 12723 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2024 | 727 | 0.040 |
Why?
|
Elastin | 1 | 2021 | 298 | 0.040 |
Why?
|
Formaldehyde | 1 | 2021 | 358 | 0.040 |
Why?
|
Electrocoagulation | 1 | 2020 | 152 | 0.040 |
Why?
|
Ethylnitrosourea | 1 | 2019 | 51 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4576 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20100 | 0.040 |
Why?
|
Cholesterol, LDL | 1 | 2008 | 2382 | 0.040 |
Why?
|
Time Factors | 2 | 2020 | 39969 | 0.040 |
Why?
|
Alkylating Agents | 1 | 2019 | 133 | 0.040 |
Why?
|
Adolescent | 4 | 2019 | 88326 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2022 | 1096 | 0.040 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2019 | 99 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2014 | 4317 | 0.040 |
Why?
|
Republic of Korea | 1 | 2020 | 590 | 0.040 |
Why?
|
Organizational Objectives | 1 | 2020 | 426 | 0.040 |
Why?
|
Prevalence | 1 | 2015 | 15733 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2005 | 1301 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2008 | 2639 | 0.040 |
Why?
|
Lasers, Solid-State | 1 | 2020 | 176 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2021 | 499 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39106 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2021 | 1126 | 0.040 |
Why?
|
Acrylamides | 1 | 2019 | 260 | 0.040 |
Why?
|
Inflammation | 2 | 2021 | 10774 | 0.040 |
Why?
|
Immunity, Innate | 2 | 2011 | 3066 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2003 | 1601 | 0.040 |
Why?
|
Reference Standards | 1 | 2021 | 1003 | 0.040 |
Why?
|
Pilot Projects | 2 | 2021 | 8633 | 0.040 |
Why?
|
Amino Acids | 1 | 2023 | 1718 | 0.030 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 385 | 0.030 |
Why?
|
World Health Organization | 1 | 2023 | 1322 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2003 | 1787 | 0.030 |
Why?
|
Retreatment | 1 | 2018 | 598 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2007 | 5870 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 954 | 0.030 |
Why?
|
Incidental Findings | 1 | 2021 | 697 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2021 | 999 | 0.030 |
Why?
|
Fibroblast Growth Factors | 1 | 2021 | 867 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5821 | 0.030 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2017 | 239 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2018 | 8554 | 0.030 |
Why?
|
Mutagenesis | 1 | 2019 | 1232 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 931 | 0.030 |
Why?
|
Models, Biological | 2 | 2018 | 9469 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2023 | 1334 | 0.030 |
Why?
|
Capnography | 1 | 2014 | 91 | 0.030 |
Why?
|
Medical Errors | 1 | 2022 | 1263 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2015 | 9032 | 0.030 |
Why?
|
Etoposide | 1 | 2015 | 634 | 0.030 |
Why?
|
Phosphorylation | 2 | 2015 | 8321 | 0.030 |
Why?
|
Radiography | 2 | 2015 | 6965 | 0.030 |
Why?
|
bcl-X Protein | 1 | 2015 | 410 | 0.030 |
Why?
|
Luciferases | 1 | 2015 | 714 | 0.030 |
Why?
|
Fibrosis | 1 | 2020 | 2049 | 0.030 |
Why?
|
Video-Assisted Surgery | 1 | 2013 | 51 | 0.030 |
Why?
|
Risk Assessment | 3 | 2023 | 23996 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3162 | 0.030 |
Why?
|
Autoantibodies | 1 | 2021 | 2118 | 0.030 |
Why?
|
Cerebral Angiography | 1 | 2018 | 1281 | 0.030 |
Why?
|
Mitral Valve | 1 | 2021 | 1465 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2003 | 3113 | 0.030 |
Why?
|
Thymectomy | 1 | 2013 | 195 | 0.030 |
Why?
|
Antilymphocyte Serum | 1 | 2014 | 487 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4853 | 0.020 |
Why?
|
Cytokines | 1 | 2007 | 7396 | 0.020 |
Why?
|
Carboplatin | 1 | 2015 | 794 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 349 | 0.020 |
Why?
|
Hospitals, University | 1 | 2013 | 564 | 0.020 |
Why?
|
Polypharmacy | 1 | 2014 | 306 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 709 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 2828 | 0.020 |
Why?
|
Observer Variation | 1 | 2017 | 2606 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2467 | 0.020 |
Why?
|
Strongyloides stercoralis | 1 | 2010 | 23 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3605 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1563 | 0.020 |
Why?
|
Waiting Lists | 1 | 2014 | 765 | 0.020 |
Why?
|
Sex Factors | 1 | 2003 | 10554 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2020 | 0.020 |
Why?
|
Rare Diseases | 1 | 2014 | 622 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2850 | 0.020 |
Why?
|
Patient Care Team | 1 | 2020 | 2521 | 0.020 |
Why?
|
Cryosurgery | 1 | 2014 | 474 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 1612 | 0.020 |
Why?
|
Gene Expression | 1 | 2021 | 7581 | 0.020 |
Why?
|
Quinazolines | 1 | 2015 | 1371 | 0.020 |
Why?
|
Signal Transduction | 3 | 2018 | 23447 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1406 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2014 | 625 | 0.020 |
Why?
|
Hot Temperature | 1 | 2014 | 1440 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 1609 | 0.020 |
Why?
|
Oncogenes | 1 | 2013 | 1222 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3597 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5035 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 54423 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8002 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2021 | 12794 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3606 | 0.020 |
Why?
|
Respiratory Insufficiency | 1 | 2014 | 1230 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5791 | 0.020 |
Why?
|
Ultrasonography | 1 | 2018 | 5971 | 0.020 |
Why?
|
Sulfonamides | 1 | 2015 | 1979 | 0.020 |
Why?
|
RNA Interference | 1 | 2013 | 2832 | 0.010 |
Why?
|
Up-Regulation | 1 | 2013 | 4125 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6484 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6075 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10766 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2019 | 18966 | 0.010 |
Why?
|
Immunization | 1 | 2007 | 1227 | 0.010 |
Why?
|
Liver Transplantation | 1 | 2014 | 2330 | 0.010 |
Why?
|
Recurrence | 1 | 2015 | 8466 | 0.010 |
Why?
|
Oxygen | 1 | 2014 | 4227 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2024 | 15633 | 0.010 |
Why?
|
Self Report | 1 | 2013 | 3725 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8656 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5205 | 0.010 |
Why?
|
Vitamin D | 1 | 2014 | 3303 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15601 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 41495 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15843 | 0.010 |
Why?
|
Schizophrenia | 1 | 2014 | 6937 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2007 | 4758 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16592 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2014 | 11461 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 42232 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2007 | 10194 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2013 | 21019 | 0.000 |
Why?
|